Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Fouquet, Guillemette  [Clear All Filters]
2015
D'Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Sousa PSantos E, Bruneau J, Fouquet G, Zavala F, et al. G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease. Sci Transl Med. 2015;7(281):281ra42.
2018
Fouquet G, Coman T, Hermine O, Côté F. Serotonin, hematopoiesis and stem cells. Pharmacol Res. 2018.
2020
Van de Wyngaert Z, Nerich V, Fouquet G, Chrétien M-L, Caillot D, Azar N, Garderet L, Lenain P, Macro M, Bourhis J-H, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplant. 2020.
2021
Cohen C, Coulon S, Bhukhai K, Neuraz A, Dussiot M, Fouquet G, Le Stang M-B, Flamant M, Vrtovsnik F, Hummel A, et al. Erythrocytosis associated with IgA nephropathy. EBioMedicine. 2021;75:103785.
2023
Salmanton-García J, Marchesi F, Koehler P, Weinbergerova B, Colović N, Falces-Romero I, Buquicchio C, Farina F, VAN Praet J, Biernat MM, et al. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
2024
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Aiello TFrancesco, Salmanton-García J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, Farina F, Dávila-Valls J, Martín-Pérez S, El-Ashwah S, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Ghanem R, Glaisner S, Bobin A, Ronchetti A-M, Cereja S, Joly B, Salanoubat C, Fouquet G. Posterior reversible encephalopathy syndrome (PRES) and myeloma. Leuk Res Rep. 2024;21:100407.